Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ImmunityBio, Inc. < Previous 1 2 Next > ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval August 12, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer August 06, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors June 20, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update June 07, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast May 17, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® May 07, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types May 02, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association April 30, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer April 25, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 22, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG February 05, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million January 02, 2024 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference November 16, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity November 07, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date October 26, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ October 23, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities September 11, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Names Enrique Diloné as Chief Technology Officer August 03, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors July 20, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients July 10, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Participate in the Jefferies Global Healthcare Conference May 22, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome April 25, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University April 24, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU February 16, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors February 15, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration January 19, 2023 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor December 12, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference November 17, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio to Participate in the Jefferies London Healthcare Conference October 27, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting June 06, 2022 From ImmunityBio, Inc. Via Business Wire Tickers IBRX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.